Apyx Medical Corp. (APYX) Tops Q4 EPS by 3c, Revenues beat; Offers Q1 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Apyx Medical Corporation Reports Fourth Quarter and Full Year of 2019 Preliminary Unaudited Financial Results and Introduces First Quarter of Fiscal Year 2020 Financial Outlook
March 16, 2020 4:05 PM EDTAdvanced Energy Sales increase 58% year-over-year in Q4 and increase 73% year-over-year in FY'19
CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ: APYX) (the Company), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported preliminary unaudited financial results for its fourth quarter and fiscal year ended December 31, 2019 and introduced financial expectations for the first quarter ending March 31, 2020.
The financial information contained herein are... More
